Fundz
Real-time · AI · Cross-signal

Discover the power of real-time signals plus AI

Every contract, funding round, exec hire, and M&A move on Chrysalis Bio Therapeutics — with verified, ICP-scored contact reveals (email + mobile) on demand.

Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.

See plansBook a 15-min walkthrough
▶
Watch the 2-minute tour · with sound

Chrysalis BioTherapeutics, Inc. Collaborates with NIAID to Evaluate Chrysalin® for Treatment of Cutaneous Radiation Injury

Nov 18, 2024•over 1 year ago

Contract Type

collaboration

GalvestonBiotechnologyHealthcare

Description

Chrysalis BioTherapeutics, Inc. has signed a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) for evaluating Chrysalin for the treatment of Cutaneous Radiation Injury (CRI). The collaboration aims to assess the potential of Chrysalin in reversing radiation-induced inflammation and dermal injury caused by RCI.

Company Information

Company

Chrysalis Bio Therapeutics

Location

2200 MARKET ST, SUITE 606

Galveston, Texas, United States

About

Chrysalis BioTherapeutics, Inc. is a biopharmaceutical development company located in Galveston, TX. TP508 (rusalatide acetate) is licensed from The University of Texas Medical Branch (UTMB) at Galveston, TX. Although TP508 has shown potential efficacy in stimulating early tissue repair in human clinical trials, it is not yet FDA-approved and is currently only available for investigational use.

Predictive Intelligence
Strategic

ML-powered predictions for Chrysalis Bio Therapeutics's next move

Learn about Strategic plan

Related People

Suggested for you

Sign in to view contact details

Sign in to view contact details

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months